BridgeBio Pharma (BBIO) Minority Interest (2017 - 2026)

BridgeBio Pharma has disclosed Minority Interest across 10 years of filings, most recently posting $10.4 million for Q1 2026.

• Minority Interest for Q1 2026 came in at $10.4 million, up 4.84% year-over-year; the trailing twelve-month figure through Mar 2026 was $10.4 million (up 4.84% YoY), and the FY2025 annual result was $10.6 million, up 4.42% from the prior year.
• Minority Interest came in at $10.4 million for Q1 2026 at BridgeBio Pharma, down from $10.6 million in the prior quarter.
• In the past five years, Minority Interest ranged from a high of $12.4 million in Q3 2023 to a low of -$27000.0 in Q1 2022.
• The 5-year median for Minority Interest is $10.9 million (2024), against an average of $10.4 million.
• Across the five-year window, Minority Interest tumbled 102.12% in 2022 and surged 45492.59% in 2023, its largest moves.
• BridgeBio Pharma's Minority Interest stood at $11.3 million in 2022, then slipped by 0.34% to $11.2 million in 2023, then slipped by 9.73% to $10.2 million in 2024, then increased by 4.42% to $10.6 million in 2025, then slipped by 1.51% to $10.4 million in 2026.
• The last three Minority Interest figures came in at $10.4 million (Q1 2026), $10.6 million (Q4 2025), and $10.3 million (Q3 2025), per Business Quant data.